| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2008-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_759a844bf92aa65d87a5ea95f3796acc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb578b73c47ffacc574b5bdaf0999a7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfb8800a93fcb72fddb31231bd4156c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc0d1c3e544e1fd0afc69f016e20d344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9ebf584ee69d202185b80c81425b97d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fa67f4c80a7656da3b41e1f503d5952
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f59962a1271a43c68f0dd16330facde0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dd91f98464384df17cbd9eb6a2dda42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0323d7bbb6ac74f9fdd520355f35c7d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b88751f88a9aef3bd8574e1a924c79b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03858736063929d7b381e0d13058ebc3 |
| publicationDate |
2013-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2559771-A3 |
| titleOfInvention |
Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| abstract |
IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer. |
| priorityDate |
2007-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |